SCHEMBL5259449

SCHEMBL5259449

FC(F)(F)c1cccc(-c2cnc3ncccn23)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.64
DYRK1A Q13627 5/20 0.49
DYRK2 Q92630 4/20 0.49
PKM P14618 1/20 0.48
CCNA2 P20248 3/20 0.48
CDK2 P24941 3/20 0.48
CDK5 Q00535 3/20 0.48
CDK5R1 Q15078 3/20 0.48
DYRK1B Q9Y463 3/20 0.48
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
DYRK3 O43781 2/20 0.45
CCNT1 O60563 2/20 0.45
CDK9 P50750 2/20 0.45
KDM4E B2RXH2 3/20 0.44
MAOB P27338 1/20 0.44
GABRA1 P14867 3/20 0.44
GABRG2 P18507 3/20 0.44
GABRB3 P28472 3/20 0.44
GABRA3 P34903 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9870207 0.83 KDM4E (0.49) BACE1DYRK1ADYRK2CCNA2CDK2
SCHEMBL5262408 0.81 GABRA1 (0.64) GABRA1GABRG2GABRB3GABRA3GABRA5
SCHEMBL2650737 0.78 BACE1 (0.77) BACE1DYRK1APKMDYRK1BGAA
SCHEMBL9870239 0.75 KDM4E (0.43) DYRK1ADYRK2CCNA2CDK2CDK5
SCHEMBL5259833 0.73 DYRK1A (0.58) BACE1DYRK1ADYRK2CCNA2CDK2
SCHEMBL22394780 0.72 BACE1 (0.67) BACE1DYRK1APKMMAPTKDM4E
SCHEMBL5418682 0.72 FLT3 (0.49) DYRK1ADYRK2CCNA2CDK2CDK5
SCHEMBL25296092 0.71 BACE1 (0.70) BACE1DYRK1APKMGAAMAPT
SCHEMBL5905775 0.71 DYRK1A (0.51) DYRK1ADYRK2CCNA2CDK2CDK5
SCHEMBL7226061 0.70 GABRG2 (0.70) BACE1GABRA1GABRG2GABRB3GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451161-B1 IMIDAZOPYRIDINES, PYRIMIDINES AND TRIAZINES FOR ENHANCING COGNITION AS GABA-A ALPHA 5 RECEPTOR SUBTYPE LIGANDS MERCK SHARP & DOHME (GB) 2007-04-18 EP claimed
US-20060040940-A1 Imidazopyridines pyrimidines and triazines for enhancing cognition as gaba-a-alphas 5 receoptor subtype ligands BETTATI MICHELA 2006-02-23 US claimed
EP-1451161-B1 IMIDAZOPYRIDINES, PYRIMIDINES AND TRIAZINES FOR ENHANCING COGNITION AS GABA-A ALPHA 5 RECEPTOR SUBTYPE LIGANDS MERCK SHARP & DOHME (GB) 2007-04-18 EP disclosed
US-20060040940-A1 Imidazopyridines pyrimidines and triazines for enhancing cognition as gaba-a-alphas 5 receoptor subtype ligands BETTATI MICHELA 2006-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040940-A1 Imidazopyridines pyrimidines and triazines for enhancing cognition as gaba-a-alphas 5 receoptor subtype ligands CHRNA3, GABRA3, GABRB3 BACE1 1186/4885DYRK1A 2184/4885DYRK2 2994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.